cent ives ▁given ▁to ▁ph arma ce ut ical ▁companies ▁to ▁produce ▁or phan ▁dru gs ▁have ▁led ▁to ▁the ▁impression ▁that ▁the ▁financial ▁support ▁afford ed ▁to ▁make ▁these ▁dru gs ▁possible ▁is ▁a kin ▁to ▁ab use . ▁Because ▁dru gs ▁can ▁be ▁used ▁to ▁treat ▁multiple ▁conditions , ▁companies ▁can ▁take ▁dru gs ▁that ▁were ▁file d ▁with ▁their ▁government ▁ag ency ▁as ▁or phan ▁dru gs ▁to ▁receive ▁financial ▁assistance , ▁and ▁then ▁market ▁it ▁to ▁a ▁wide ▁population ▁to ▁increase ▁their ▁profit ▁margin . ▁For ▁example ▁A stra Z en eca ' s ▁ch ol ester ol ▁drug ▁C rest or ▁was ▁file d ▁as ▁a ▁treatment ▁for ▁the ▁rare ▁disease ▁ped iat ric ▁famil ial ▁hyper ch ol est ero lem ia . ▁After ▁the ▁drug ▁was ▁approved ▁for ▁or phan ▁drug ▁design ation , ▁and ▁A stra Z en eca ▁had ▁received ▁tax ▁breaks ▁and ▁other ▁advantages , ▁A stra Z en eca ▁later ▁applied ▁and ▁received ▁F DA ▁appro val ▁for ▁the ▁drug ▁to ▁be ▁used ▁to ▁treat ▁ch ol ester ol ▁in ▁all ▁di abet ics . ▁ ▁N ICE ▁ ▁By ▁ 2 0 0 8 ▁if ▁an ▁or phan ▁drug ▁cost ▁more ▁than ▁£ 3 0 , 0 0 0 ▁the ▁N ICE ▁required ▁other ▁arguments ▁for ▁fund ing . ▁ ▁In ▁ 2 0 1 5 , ▁N ICE ▁held ▁consult ations ▁with ▁" pat ient ▁groups , ▁the ▁Department ▁of ▁Health , ▁companies , ▁learned ▁soci eties , ▁char ities